Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.Â
For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that... […]
An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice—a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected—regarding the use of artificial intelligence methods to more accurately diagnose, monitor, and treat brain cancer patients. The team recently published two companion... […]
OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.Â
Inflo Health, a leader in AI-driven radiology follow-up care orchestration, announced that it has qualified for the American College of Radiology’s Learning Network Vendor Partner designation on the heels of a successful collaboration that saw East Alabama Medical Center significantly improve recommendations follow-up rates.Â
David BakerPhoto credit: Niklas Elmehed © Nobel Prize OutreachDemis HassabisPhoto credit: Niklas Elmehed © Nobel Prize OutreachJohn M. JumperPhoto credit: Niklas Elmehed © Nobel Prize OutreachDavid Baker, Demis Hassabis, and John M. Jumper received the 2024 Nobel Prize in Chemistry for their work in protein design and prediction.Â
Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.Â
Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.
New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit.Â
